Teva Pharmaceutical Industries News

Shares of Teva Pharmaceutical Industries Ltd opened at 38.61 on Friday. Teva Pharmaceutical Industries Ltd has a one year low of $35.00 and a one year high of $51.15. The company has a market cap of $33.629 billion and a P/E ratio of 12.02. Teva Pharmaceutical Industries Ltd last issued its quarterly earnings data on Wednesday, May 9th.

Teva Pharmaceuticals Industries Ltd. fell for a fourth week in New York, its longest losing streak since November, as the Israeli drug maker's guidance cut spurred Piper Jaffray & Co.

The analysts wrote, "We lowered our 2012E EPS on TEVA by to $5.40 compared to TEVA's rebased 2012E EPS range of $5.30 -$5.40 vs.

The firm currently has a "buy" rating on the stock. Shares of Teva Pharmaceutical Industries Ltd traded up 1.09% during mid-day trading on Friday, hitting $39.11. Teva Pharmaceutical Industries Ltd has a 52 week low of $35.00 and a 52 week high of $51.15. The company has a market cap of $34.065 billion and a P/E ratio of 12.02. Teva Pharmaceutical ... (more)

Apple Inc. : Piper Jaffray this morning in a note to investors highlighted the reasons for why it looks for Apple shares to reach $1,000 in the next couple of years.

Leap Wireless International Inc. : Jefferies believes Leap's market opportunity and growth potential may be limited as the major carriers increasingly focus on the pre-paid market to drive growth.

Teva Pharmaceuticals Ltd.'s new chief executive officer, Jeremy Levin, said Thursday that he has changed the leadership lineup in hopes of regaining more of the U.S. generic drug market, in which Teva has dominated for years but now faces increasing competition.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia JERUSALEM-- --Teva Pharmaceutical Industries Ltd.

Patterson Companies Inc. : After Paterson Companies reported results that beat consensus, Barrington noted the company's 6% growth in sales of dental equipment and software was driven by CEREC and digital radiography products.

May 23--Teva Pharmaceutical Industries Ltd. will enter the personalized medicine field, which will have high efficiency to cost ratios, albeit limited market segments, says Harel Finance analyst Steven Tepper following yesterday's speech by new Teva president and CEO Dr.

Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 JERUSALEM -- -- On its conference call today, Teva Pharmaceutical Industries Ltd.

The companies whose shares are moving in pre-market trade Thursday are: Hewlett-Packard Company, Activision Blizzard Inc, Teva Pharmaceutical Industries Ltd, Arch Coal Inc, Aviva Plc, Siemens AG and Hewlett-Packard Company stock climbed 8.63 percent to $22.90 in pre-market session.

Shares of Teva Pharmaceutical Industries Ltd opened at 39.18 on Wednesday. Teva Pharmaceutical Industries Ltd has a 52 week low of $35.00 and a 52 week high of $51.15. The company has a market cap of $34.126 billion and a P/E ratio of 12.18. Teva Pharmaceutical Industries Ltd last announced its earnings results on Wednesday, May 9th.

BioLineRx Ltd., an Israeli drug development company partly held by Teva Pharmaceutical Industries Ltd., said it's been approached by larger drugmakers interested in developing its experimental schizophrenia pill.

Investors may be a bit weary of jumping into PROLOR Biotech after the company announced the closing an underwritten public offering, but that hasn't kept billionaire Phil Frost, chairman of generic drugmaker Teva Pharmaceutical Industries from buying another big chunk of the company.

Teva Pharmaceuticals has seen its stock make two significant moves away from the S&P 500 over the past six months.

This represents approximately two times the equity's expected intraday call activity.

The popular blood thinning drug known as Plavix that sells for about $200 for a one month supply is about to go generic, dropping the price by as much 75 percent, and giving those who take the drug to reduce their risk of stroke and heart attack a little less stress at the checkout counter.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Teva Pharmaceutical Industries Limited 's Board of Directors Votes to Re-Elect Dr.

12 to regain compliance. Aeterna said it will monitor the price and consider its options.